Haruta Munenori, Otsubo Shigeru, Otsubo Yuriko
Department of Clinical Engineering, Faculty of Human Care at Makuhari, Tohto University, 1-1 Hibino, Mihama-Ward, Chiba-City, Chiba-Prefecture 261-0021 Japan.
Department of Nephrology, Sangenjaya Hospital, Tokyo, Japan.
Ren Replace Ther. 2022;8(1):61. doi: 10.1186/s41100-022-00451-2. Epub 2022 Dec 2.
We examined the clinical characteristics of hemodialysis patients with COVID-19 during the 6th wave of infection (mainly Omicron variant) in Japan.
Hemodialysis patients admitted in January 2022 and thereafter were grouped as the 6th wave group ( = 53), while others were grouped as the 1st-5th wave group ( = 47).
The proportion of vaccinations was significantly higher in the 6th wave group than in the 1st-5th wave group (96.2% vs 10.6%, < 0.0001). Neutralizing antibody and molnupiravir were used more frequently in the 6th wave group (75.5% and 88.7%) than in the 1st-5th wave group (14.9% and 0%, both < 0.0001). The critical disease was seen in 21.3% of the patients in the 1st-5th wave group and 0% in the 6th wave group ( < 0.001).
The prognosis of hemodialysis patients in the 6th wave group was good. The vaccination and advances in the treatment may have contributed to the outcomes.
我们研究了日本第六波感染（主要为奥密克戎变种）期间新冠病毒感染的血液透析患者的临床特征。
将2022年1月及以后收治的血液透析患者归为第六波组（n = 53），其他患者归为第一至五波组（n = 47）。
第六波组的疫苗接种比例显著高于第一至五波组（96.2% 对10.6%，P < 0.0001）。第六波组中和抗体和莫努匹拉韦的使用频率（分别为75.5%和88.7%）高于第一至五波组（分别为14.9%和0%，均P < 0.0001）。第一至五波组21.3%的患者出现危重症，第六波组为0%（P < 0.001）。
第六波组血液透析患者的预后良好。疫苗接种和治疗进展可能促成了这一结果。
